Open label extension study with gefitinib (IRESSA™) for completing trial patients who may benefit from further treatment

Exclusion Criteria

• - Any evidence of clinically active interstitial lung disease (patients with chronic,stable, radiographic changes who are asymptomatic need not be excluded).
• - In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease).
• - Withdrawal, at any time, from the preceding gefitinib study.
• - Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John’s Wort